Melanoma Study Enrolled Second Patient for New Therapy
Researchers are testing a drug combination in patients with stage III melanoma to see if it can improve surgery outcomes.
Updated on Sept. 24, 2026 in Cancer
Live Poll
Do you believe experimental immunotherapy combinations are worth the risk for early-stage cancer patients?
Primmune Therapeutics has enrolled the second participant in the Phase 2 INFLECTION-003 clinical trial. This study investigates whether a combination of a new oral drug and immunotherapy can improve outcomes for patients with resectable stage III melanoma.
Why it matters
The study aims to determine if this neoadjuvant treatment approach increases major pathologic response rates before surgical intervention. This could provide a new pathway for improving success in treating advanced stage III melanoma.
The INFLECTION-003 study is a Phase 2 trial building on Phase 1 safety data collected from 118 healthy volunteers. It evaluates the impact of polvitolimod HCl combined with pembrolizumab, though results on pathologic response rates remain preliminary.
The players
Primmune Therapeutics
A biotechnology company focused on developing oral TLR7 agonists for the treatment of cancers and viral diseases.
The details
The study utilizes polvitolimod HCl, an oral TLR7/IRF7 agonist, administered alongside intravenous pembrolizumab for nine weeks. This neoadjuvant regimen is given to patients before they undergo surgical resection of their tumors to potentially improve clinical response.
Timeline
September 24, 2026: The second patient was enrolled in the Phase 2 study.
Health Landscape
This development represents a shift toward investigating oral immunotherapy agonists as neoadjuvant treatments for melanoma. It follows a growing trend of testing immune-stimulating agents in combination with existing therapies to improve surgical success rates.
This trial remains in the early stages and does not currently impact treatment options available to the public. If you are a patient with stage III melanoma, discuss the potential of neoadjuvant therapy and active clinical trials with your oncologist.
The takeaway
The INFLECTION-003 trial is currently testing if a new oral agonist combined with immunotherapy can improve surgical outcomes. Patients interested in emerging treatments for stage III melanoma should speak with their physician about eligibility for ongoing research studies.
Further reading
For more information on current treatment trends and research developments, visit the Cancer section.
More information
View the clinical study information portal to track updates on this trial.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you believe experimental immunotherapy combinations are worth the risk for early-stage cancer patients?
